XCXiaobo Chen

Xiaobo Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaobo Chen has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Zaiyi Liu

    Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; School of Medicine, South China University of Technology, Guangzhou, China; Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China

    4 shared publications
  • Changhong Liang

    Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    3 shared publications
  • Chu Han

    Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    2 shared publications
  • Huan Lin

    Department of Radiology, Guangdong Provincial Peoples Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    2 shared publications
  • Suyun Li

    Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China

    2 shared publications
  • Zeyan Xu

    Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China

    2 shared publications

Latest Publications

  • Development of Novel and Interpretable Automated Models for Predicting Total Knee Replacement in Knee Osteoarthritis: An International Multicenter Study

    by Fanfan Zhao, Yao Chen, Xiaoyue Zhou, Xiaobo Chen, Chaokang Han, Xiangjun Lu, Yaxuan Song, Chunmiao Lin, Ruozhen Gu, Fan Yang, et al.


  • Open Access

    An interpretable AI system reduces false-positive MRI diagnoses by stratifying high-risk breast lesions

    by Yanting Liang, Zhitao Wei, Yi Dai, Xiaobo Chen, Siyao Du, Chinting Wong, Zeyan Xu, Weibo Gao, Chu Han, Kexin Chen, et al.

    Breast cancer diagnosis using magnetic resonance imaging remains limited by high false-positive rates and substantial inter-reader variability, especially for lesions classified as Breast Imaging Reporting and Data System (BI-RADS) category 4, often leading to unnecessary biopsies. Here we show that the BI-RADS 4 Lesions Analysis System (BL4AS), an artificial intelligence system powered by foundation models and leveraging the rich spatiotemporal information of dynamic contrast-enhanced MRI, addresses these diagnostic challenges. Developed on a multicenter dataset of 2,803 lesions from 2,686 female patients, BL4AS demonstrates robust performance with areas under the curve of 0.892-0.930 and significantly outperforms radiologists in specificity (0.889 versus 0.491). BL4AS-assisted interpretation significantly improves diagnostic accuracy for both senior and junior radiologists, reducing inter-reader variability by 24.5% and decreasing false-positive rates by 27.3%. BL4AS further stratifies lesions into subcategories (4 A, 4B and 4 C) for refined risk assessment, offering a practical tool for precision breast cancer management.


  • Open Access

    Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer

    by Zongchao Mo, Mei Yang, Zhihan Zhu, Minghao Wang, Haoyu Wang, Zhanye Zhang, Shanshan Lyu, Fangping Xu, Haixia Shang, Huan Lin, et al.

    Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.


  • Open Access

    Multimodal data integration for biologically-relevant artificial intelligence to guide adjuvant chemotherapy in stage II colorectal cancer

    by Chenyi Xie, Ziyu Ning, Ting Guo, Lisha Yao, Xiaobo Chen, Wanghong Huang, Suyun Li, Jiahui Chen, Ke Zhao, Xiuwu Bian, et al.


  • Open Access

    Development and validation of an MRI radiomics-based interpretable machine learning model for predicting the progression-free survival in locally advanced nasopharyngeal carcinoma

    by Penghao Lai, Xiaobo Chen, Wei Pei, Xia Huang, Zhen Fang, Fan Yang, Yujie Ying, Yaxuan Song, Weifeng Jin, Shaolu Lu, et al.

    Background: Locally advanced nasopharyngeal carcinoma (LANPC) is a common malignant tumor of the nasopharynx, characterized by poor prognosis and a high susceptibility to recurrence and metastasis after surgery. The aim of this study was to establish and validate a radiomics model based on clinicopathological data and magnetic resonance imaging (MRI) information to predict progression-free survival (PFS) in LANPC patients, and to reveal the internal prediction process of the model through SHapley Additive exPlanation (SHAP) and image visualization techniques. Methods: A total of 1,098 patients with pathologically and clinically diagnosed LANPC were recruited from three hospitals {training, n=700 [70% from hospitals I (Guangxi Medical University Cancer Hospital) and II (Wuzhou Red Cross Hospital)]; internal validation, n=300 (remaining 30%); and external validation, n=98 [hospital III (The Second Affiliated Hospital of Guangxi Medical University)]}. Univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) Cox regression were used to select radiomics features. A combined model integrating the radiomics score (radscore) and important clinicopathological factors was constructed using the eXtreme Gradient Boosting (XGBoost) algorithm. SHAP and image visualization techniques were used for interpretability analysis of prognostic models. Results: Optimal predictive performance was observed in the combined model, which integrated the radscore and important clinicopathological factors [induction chemotherapy (IC), Epstein-Barr virus (EBV)-DNA, and albumin], with Harrell concordance index (C-index) values of 0.762, 0.729, and 0.752 in the training, internal, and external validation cohorts, respectively. Ten radiomics features with the highest predictive contributions were identified using the SHAP algorithm. Two LANPC patients with similar clinicopathological stages but distinct risk levels were selected to visualize the top three radiomics features, revealing notable pixel-level visual differences in the largest layer of the tumor images. Kaplan-Meier survival analysis revealed prognostic differences between low- and high-risk groups, and the model’s performance was stable across subgroups (all log-rank PConclusions: The interpretable model was able to accurately predict the PFS in LANPC patients. SHAP and image visualization techniques provided quantitative contribution values and image-level radiomics information, which could provide valuable additional information for individualized prognostic evaluation and clinical decision-making for patients with LANPC.


  • Multimodal radiomics and nomogram‐based prediction of axillary lymph node metastasis in breast cancer: An analysis considering optimal peritumoral region

    by Yayang Duan, Xiaobo Chen, Wanyan Li, Siyao Li, Chaoxue Zhang

    Purpose: To explore the optimal peri‐tumoral regions on ultrasound (US) images and investigate the performance of multimodal radiomics for predicting axillary lymph node metastasis (ALNM).Methods: This retrospective study included 326 patients (training cohort: n = 162, internal validation cohort: n = 74, external validation cohort: n = 90). Intra‐tumoral region of interests (ROIs) were delineated on US and digital mammography (DM) images. Peri‐tumoral ROI (PTR) on US images were gained by dilating actual 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 3.5 mm radius surrounding the tumor. Support vector machine (SVM) method was used to calculate the importance of radiomics features and to pick the 10 most important. Recursive feature elimination‐SVM was used to evaluate the efficacy of models with different feature numbers used.Results: The PTR0.5mm yielded a maximum AUC of 0.802 (95% confidence interval (CI): 0.676–0.901) within the validation cohort using SVM classifier. The multimodal radiomics (intra‐tumoral US and DM and US‐based PTR0.5mm radiomics model) achieved the highest predictive ability (AUC = 0.888/0.844/0.835 and 95% CI = 0.829–0.936/0.741–0.929/0.752–0.896 for training/internal validation/external validation cohort, respectively).Conclusion: The PTR0.5mm could be the optimal area for predicting ALNM. A favorable predictive accuracy for predicting ALNM was achieved using multimodal radiomics and its based nomogram.


  • Top Cited Papers

    MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer

    by Zhenwei Shi, Xiaomei Huang, Ziliang Cheng, Zeyan Xu, Huan Lin, Chen Liu, Xiaobo Chen, Chunling Liu, Changhong Liang, Cheng Lu, et al.

    Background Breast cancer is highly heterogeneous, resulting in different treatment responses to neoadjuvant chemotherapy (NAC) among patients. A noninvasive quantitative measure of intratumoral heterogeneity (ITH) may be valuable for predicting treatment response. Purpose To develop a quantitative measure of ITH on pretreatment MRI scans and test its performance for predicting pathologic complete response (pCR) after NAC in patients with breast cancer. Materials and Methods Pretreatment MRI scans were retrospectively acquired in patients with breast cancer who received NAC followed by surgery at multiple centers from January 2000 to September 2020. Conventional radiomics (hereafter, C-radiomics) and intratumoral ecological diversity features were extracted from the MRI scans, and output probabilities of imaging-based decision tree models were used to generate a C-radiomics score and ITH index. Multivariable logistic regression analysis was used to identify variables associated with pCR, and significant variables, including clinicopathologic variables, C-radiomics score, and ITH index, were combined into a predictive model for which performance was assessed using the area under the receiver operating characteristic curve (AUC). Results The training data set was comprised of 335 patients (median age, 48 years [IQR, 42-54 years]) from centers A and B, and 590, 280, and 384 patients (median age, 48 years [IQR, 41-55 years]) were included in the three external test data sets. Molecular subtype (odds ratio [OR] range, 4.76-8.39 [95% CI: 1.79, 24.21]; all P < .01), ITH index (OR, 30.05 [95% CI: 8.43, 122.64]; P < .001), and C-radiomics score (OR, 29.90 [95% CI: 12.04, 81.70]; P < .001) were independently associated with the odds of achieving pCR. The combined model showed good performance for predicting pCR to NAC in the training data set (AUC, 0.90) and external test data sets (AUC range, 0.83-0.87). Conclusion A model that combined an index created from pretreatment MRI-based imaging features quantitating ITH, C-radiomics score, and clinicopathologic variables showed good performance for predicting pCR to NAC in patients with breast cancer. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rauch in this issue.


  • Open Access

    Abstract 3115: Establishment and characterization of patient-derived breast cancer models for cancer studies

    by Leilei Chen, Xueying Yang, Likun Zhang, Xiaobo Chen, Henry Q.X. Li, Jingjing Wang

    BACKGROUND: Despite the progress and development of targeted agents and Immunotherapeutics, breast cancer is still the leading cause of death among women worldwide. At present, targeted therapy for breast cancers include endocrine blockage therapy for estrogen receptor positive (ER+) tumors and trastuzumab or lapatinib for HER2 positive (HER2+) tumors and CDK inhibitors for HER negative (HER-) tumors as well as PARP inhibitors for BRCA1/2 mutations. There is still a high unmet need for triple negative breast cancer (TNBC) and relapsed breast cancers with specific mutations. Breast cancer is a highly heterogeneous disease and reliable breast cancer models are needed to develop new clinical therapies and better reflect tumor biology. Patient-derived xenograft (PDX) models have been widely used for understanding tumor characteristics and represent human heterogeneity more faithfully and thus are suitable for mouse clinical studies for predicting drug efficacy in the clinic. Here we report the establishment and characterization of a panel of breast cancer (BC) PDX for preclinical research. METHODS: Tumor samples from patients’ breast tumor or metastastic lesion obtained via surgery, biopsy, or pleural effusions/ascites were engrafted subcutaneously in immunodeficient mice to establish PDX models. The models were classified and characterized by histopathology, immunohistochemistry (IHC), and breast cancer specific biomarkers such as estrogen receptor (ER), progesterone receptor (PR) and HER2. Genomic analysis of these models was performed by next generation sequencing (NGS). In these breast cancer models, the effects of estrogen on tumor growth and targeted endocrine therapy such as Fulvestrant were evaluated. The change of tumor volume over time was used to determine the growth rate and response to treatment in mice. RESULTS: A series of BC PDX models derived from primary patient breast tumor or metastatic lesions were successfully established and characterized. Key characteristics of parental tumors, such as histopathology, clinical markers, gene expression and copy number, as well as estrogen dependence was retained. The IHC data indicated various expression levels of ER, PR and HER2 across the panel, with TNBC being the dominant subtype. ESR1 mutation, which may play an important role in BC progression and endocrine therapy resistance, was also identified in an estrogen-independent model. In vivo, these models showed distinct tumor growth rates and different pharmacodynamic responses to standard of care agents. For example, ESR1 mutant model was responsive to Fulvestrant. CONCLUSIONS: The established BC PDX panel represent a range or ER/PR/HER2 expression status from primary and advanced cancer providing a series of preclinical models for breast cancer research and potential for mouse clinical trial enrollment. Citation Format: Leilei Chen, Xueying Yang, Likun Zhang, Xiaobo Chen, Henry Q.X. Li, Jingjing Wang. Establishment and characterization of patient-derived breast cancer models for cancer studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3115.

  • Clinical and prognostic significance of Arl4c expression in colorectal cancer

    by Xiaobo Chen, Zhaoliang Su, Shengjun Wang, Huaxi Xu

    BACKGROUND: ADP-ribosylation factor (ARF)-like 4c (Arl4c) has been reported to promote tumorigenesis in colorectal and lung cancers and may represent a novel therapeutic target. The aim of this study was to investigate the expression of ADP-ribosylat